2021_1q_omron_e
26/37 - OMRON Strengths: Focusing on Post-COVID-19 Opportunities

【テロップ】
※各テロップ文字をクリックすると該当の場所がピンポイントで閲覧できます。



【ノート】
OMRON has a global share of 50% in home-use BPMs. Annual sales volume is 21.5 million units. This is OMRON’s greatest strength in HCB. This dominant share is supported by the 600,000 retailers in 120 countries around the world. HCB is also seeing an increase in online sales, and is expanding its global online coverage. In FY2016 we launched OMRON connect, an app that records BP readings and supports visualization. Total downloads exceed 1.9 million. This data is being leveraged in many apps around the world, through collaborations with service providers. This activity is rated highly by medical practitioners around the world and has contributed significantly to improved brand recognition. Leveraging this strong brand recognition and customer base, OMRON has been developing a business model over the last few years to support remote medicine, in collaboration with its partners. The COVID-19 outbreak is accelerating the adoption of remote medicine in response to the rising risk of hospital infections amongst medical practitioners and patients. I will now explain the remote diagnostic service business model designed to tap into this demand.